NCT01518465View on ClinicalTrials.gov

Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma

PHASE2TerminatedINTERVENTIONAL

Enrollment

13

Participants

Timeline

Start Date

January 9, 2012

Primary Completion Date

December 31, 2016

Study Completion Date

October 31, 2017

Conditions

Stage I Multiple MyelomaStage II Multiple MyelomaStage III Multiple Myeloma

Interventions

DRUG

dalteparin

Given SC

DRUG

lenalidomide

Given PO

DRUG

dexamethasone

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

90033

USC/Norris Comprehensive Cancer Center, Los Angeles

Sponsors

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

collaborator

Celgene Corporation

INDUSTRY

lead

University of Southern California

OTHER